Status:
UNKNOWN
Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma
Lead Sponsor:
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Conditions:
Malignant Pleural Mesothelioma
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
This is a monocentric prospective study of radiotherapy using accelerated hypofractionation with Tomotherapy in Malignant Pleural Mesothelioma (MPM) patients after pleurectomy / decortication (P / D) ...
Detailed Description
The role of radiation therapy remains to be defined in unresected MPM or after P/D. For the latter, local control remains the primary objective but radiotherapy (RT) is a challenge because of the risk...
Eligibility Criteria
Inclusion
- Patients must have histologically or cytologically confirmed MPM
- Karnofsky Performance status scale 70-100 (see Appendix B)
- Male or female, Aged \>= 18 and ≤ 85 years
- Life expectancy greater than 6 months
- All clinical and pathological stage with the exclusion of contralateral mediastinum involvement (N3) and M1
- Patients must have normal organ and marrow function as defined below:
- leukocytes \>3,000/microL
- absolute neutrophil count \>1,500/microL
- platelets \>100,000/microL
- aspartate transaminase(AST)/alanine transaminase (ALT) \<2.5 X institutional upper limit of normal
- creatinine within normal institutional limits
- glycemia \< 100 mg/dl
- Ability to understand and the willingness to sign a written informed consent document.
- Forced expiratory volume in the 1st second(FEV1) ≥ 50
- Patients after biopsy must have measurable disease defined as at least one lesion that can be accurately measured according to modified RECIST criteria; for resected patients no more than 3 months are allowed for RT start.
- Written informed consent signed and dated before starting study procedure.
- Female participants of child bearing potential and male participants whose partner is of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study and for 4 months thereafter.
Exclusion
- Previous thorax radiotherapy
- Chemotherapy is allowed but completed 3 weeks before RT starts
- Participation in another clinical trial with any investigational agents within 30 days prior to study screening.
- Patients with M1 have to be excluded to this study
- FEV1 \< 50
- Age \>85 years old
- Respiratory needing oxygen therapy
- Interstitial pneumopathy
- Active pneumonitis
- Fissural disease
- Contralateral mediastinum involvement (N3) and M1
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Key Trial Info
Start Date :
August 14 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03269227
Start Date
August 14 2017
End Date
December 1 2023
Last Update
May 30 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
SC Radiotherapy
Meldola, Italy, 47014